Skip Navigation
Close

12 Results

Acute Lymphocytic Leukemia with Novartis Kymriah, Adult
Kymriah, developed by Novartis, is a type of immunotherapy for young adult patients (up to 25 years of age) with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Kite Yescarta, Adult
Yescarta, developed by Kite, is a type of immunotherapy for young adult patients (up to 25 years of age) with B-Cell Lymphoma. Through Yescarta therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Novartis Kymriah, Adult
Kymriah, developed by Novartis, is a type of immunotherapy for young adults (up to 25 years of age) with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Large B-Cell Lymphoma with Juno Breyanzi
Breyanzi, developed by Juno Technologies, is a type of immunotherapy for adult patients with Large B-cell Lymphoma. Through Breyanzi therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Luxturna Subretinal Injection, 1 Eye
Luxturna is a gene therapy medication treating patients with Retinitis Pigmentosa, specifically those patients with the RPE65 Gene Mutation causing vision loss. Luxturna is delivered by injecting a genetically engineered copy of the RPE65 gene directly into the patient's retina (or both retinas) with the efficacy of improving one's vision or possibly restoring vision.
Luxturna Subretinal Injection, Both Eyes
Luxturna is a gene therapy medication treating patients with Retinitis Pigmentosa, specifically those patients with the RPE65 Gene Mutation causing vision loss. Luxturna is delivered by injecting a genetically engineered copy of the RPE65 gene directly into the patient's retina (or both retinas) with the efficacy of improving one's vision or possibly restoring vision.
Mantle Cell Lymphoma with Kite Tecartus, Adult
Tecartus, developed by Kite, is a type of immunotherapy for adult patients with Mantle Cell Lymphoma. Through Tecartus therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Multiple Myeloma with Bluebird Abecma
Abecma, developed by Bluebird bio, is a type of immunotherapy for adult patients with Multiple Myeloma. Through Abecma therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Zolgensma Infusion For Spinal Muscular Atrophy, Inpatient
Zolgensma is a one-time genetic therapy for patients under two years old diagnosed with Spinal Muscular Atrophy (SMA), a condition in which the Survival Motor Neuron 1 (SMN1) gene is missing or functioning poorly. Zolgensma delivers a new gene to produce survival motor neuron protein and preserve motor neuron cells throughout the body, supporting and sustaining muscle function and stopping the progression of SMA.
Zolgensma Infusion For Spinal Muscular Atrophy, Outpatient
Zolgensma is a one-time genetic therapy for patients under two years old diagnosed with Spinal Muscular Atrophy (SMA), a condition in which the survival motor neuron 1 (SMN1) gene is missing or functioning poorly. Zolgensma delivers a new gene to produce survival motor neuron protein and preserve motor neuron cells throughout the body, supporting and sustaining muscle function and stopping the progression of SMA.